Dexamethasone Reduces Sensitivity to Cisplatin by Blunting p53-Dependent Cellular Senescence in Non-Small Cell Lung Cancer

INTRODUCTION: Dexamethasone (DEX) co-treatment has proved beneficial in NSCLC patients, improving clinical symptoms by the reduction of side effects after chemotherapy. However, recent studies have shown that DEX could render cancer cells more insensitive to cytotoxic drug therapy, but it is not kno...

Descripción completa

Detalles Bibliográficos
Autores principales: Ge, Haiyan, Ni, Songshi, Wang, Xingan, Xu, Nuo, Liu, Ying, Wang, Xun, Wang, Lingyan, Song, Dongli, Song, Yuanlin, Bai, Chunxue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3525662/
https://www.ncbi.nlm.nih.gov/pubmed/23272171
http://dx.doi.org/10.1371/journal.pone.0051821

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3525662/
https://www.ncbi.nlm.nih.gov/pubmed/23272171
http://dx.doi.org/10.1371/journal.pone.0051821

Ejemplares similares